Effectiveness of artemether-lumefantrine for treating uncomplicated malaria in low- and high-transmission areas of Ghana

• Published in: Malaria journal Vol. 23; no. 1; p. 40
• Main Authors: Mawuli, Mawusi Adepa, Amoah, Linda Eva, Cui, Liwang, Quashie, Neils Ben, Afrane, Yaw Asare
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 05.02.2024; BioMed Central; BMC
• Subjects: Antimalarials; Antimalarials - therapeutic use; Antiparasitic agents; Artemether; Artemether - therapeutic use; Artemether, Lumefantrine Drug Combination - therapeutic use; Artemether–lumefantrine; Artemisinin; Artemisinins - therapeutic use; Control; Delayed parasite clearance Ghana; Disease transmission; Dosage and administration; Drug Combinations; Ethanolamines - therapeutic use; Fluorenes - therapeutic use; Genes; Genotyping; Ghana; Health facilities; Human diseases; Humans; Identification and classification; Infections; Malaria; Malaria, Falciparum - drug therapy; Microscopy; Nucleotide sequence; Parasitemia - drug therapy; Parasites; Patients; Performance evaluation; Plasmodium falciparum; Plasmodium falciparum - genetics; Prevention; Primers; Recurrence; Risk factors; rRNA 18S; Species identification; Uncomplicated malaria; Vector-borne diseases; Ghana; Uncomplicated malaria; Delayed parasite clearance Ghana; Plasmodium falciparum; Artemether–lumefantrine
• ISSN: 1475-2875; 1475-2875
• DOI: 10.1186/s12936-024-04850-0

Artemisinin-based combination therapy (ACT) has been effective in the supervised treatment of uncomplicated malaria in Ghana. Since ACT usage is primarily unsupervised, this study aimed to determine the effectiveness of artemether-lumefantrine (AL) for treating malaria patients in two transmission settings in Ghana. Eighty-four individuals with uncomplicated Plasmodium falciparum malaria were recruited from Lekma Hospital (LH) in Accra (low-transmission area; N = 28), southern Ghana, and King's Medical Centre (KMC) in Kumbungu (high-transmission area; N = 56), northern Ghana. Participants were followed up for 28 days after unsupervised treatment with AL. The presence of asexual parasites was determined by microscopic examination of Giemsa-stained blood smears. Plasmodium species identification was confirmed using species-specific primers targeting the 18S rRNA gene. Parasite recrudescence or reinfection was determined by genotyping the Pfmsp 1 and Pfmsp 2 genes. After AL treatment, 3.6% (2/56) of the patients from KMC were parasitaemic on day 3 compared to none from the LH patients. One patient from KMC with delayed parasite clearance on day 3 remained parasite-positive by microscopy on day 7 but was parasite-free by day 14. While none of the patients from LH experienced parasite recurrence during the 28-day follow-up, three and two patients from KMC had recurrent parasitaemia on days 21 and 28, respectively. Percentage reduction in parasite densities from day 1, 2, and 3 for participants from the KMC was 63.2%, 89.5%, and 84.5%. Parasite densities for participants from the LH reduced from 98.2%, 99.8% on day 1, and 2 to 100% on day 3. The 28-day cumulative incidence rate of treatment failure for KMC was 12.8% (95% confidence interval: 1.9-23.7%), while the per-protocol effectiveness of AL in KMC was 89.47%. All recurrent cases were assigned to recrudescence after parasite genotyping by Pfmsp 1 and Pfmsp 2. While AL is efficacious in treating uncomplicated malaria in Ghana, when taken under unsupervised conditions, it showed an 89.4% PCR-corrected cure rate in northern Ghana, which is slightly below the WHO-defined threshold.